The Acne Vulgaris Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acne Vulgaris Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acne Vulgaris Market.

Some of the key takeaways from the Acne Vulgaris Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acne Vulgaris treatment therapies with a considerable amount of success over the years.

• Acne Vulgaris companies working in the treatment market are BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others, are developing therapies for the Acne Vulgaris treatment

• Emerging Acne Vulgaris therapies in the different phases of clinical trials are- BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others are expected to have a significant impact on the Acne Vulgaris market in the coming years.

• In June 2025, Sagimet Bioscience’s oral therapy denifanstat, designed as a once-daily pill for acne, met its primary goal in a Phase III trial. Conducted by Ascletis Bioscience in China (NCT06192264), the study showed a 33.2% treatment success rate in acne vulgaris patients after 12 weeks, compared to 14.6% with placebo. Treatment success—one of three primary endpoints—was determined by skin clearance scores. Following these positive results, Ascletis plans to file for regulatory approval in China.

• In May 2025, Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on photodynamic therapy (PDT), announced that its updated Ameluz® nanoemulsion gel—now formulated without propylene glycol—has secured patent protection until December 2043. The formulation, already FDA-approved and available since 2024, now gains extended exclusivity against generic competition. Additionally, the company reported the completion of patient enrollment in its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of moderate to severe acne vulgaris.

• In July 2024, Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focused on treating medical and aesthetic skin conditions, announced that it has successfully enrolled 50% of patients in its pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) study. This study evaluates DMT310, a novel, once-weekly topical treatment for moderate-to-severe acne. The STAR-1 study is the first of two Phase 3 trials that, if successful, will support the Company’s filing of a new drug application (NDA) for DMT310 to treat moderate-to-severe acne.

Acne Vulgaris Overview

Acne vulgaris, commonly referred to as acne, is a chronic inflammatory skin condition that primarily affects the face, neck, chest, back, and shoulders. It is characterized by the formation of comedones (such as blackheads and whiteheads), papules, pustules, nodules, and occasionally cysts.

Get a Free Sample PDF Report to know more about Acne Vulgaris Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight

Emerging Acne Vulgaris Drugs Under Different Phases of Clinical Development Include:

• BPX-01: BioPharmX

• IDP-120: Bausch Health Americas, Inc.

• GT20029: Kintor Pharma

• KX-826: KintorPharma

• S6G5T-3: Sol-Gel Technologies, Ltd.

• ASC40: Ascletis Pharma

• GK530G: Galderma R&D

• Dapsone: Torrent Pharma

• DMT310: Dermata Therapeutics

• CD5789 (trifarotene): Galderma R&D

• Afamelanotide: Clinuvel Pharma

• NVN1000: Novan, Inc.

• Hydrogen Peroxide: Dermata Therapeutics

• Trifarotene Cream: Galderma R&D

• S6G5T-3: Accelovance

• GDC 268 Lotion: Balmoral Medical

• Isotretinoin: Vyne Therapeutics Inc.

• gevokizumab: XOMA (US) LLC

• BLI1100: Braintree Laboratories

• AKLIEF®: Teva Pharma

• Imsidolimab: AnaptysBio, Inc.

• RA-18C3: Janssen Research

• FMX101: Cutia Therapeutics

• IDP-126: Bausch Health

Acne Vulgaris Route of Administration

Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

Acne Vulgaris Molecule Type

Acne Vulgaris Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Acne Vulgaris Pipeline Therapeutics Assessment

• Acne Vulgaris Assessment by Product Type

• Acne Vulgaris By Stage and Product Type

• Acne Vulgaris Assessment by Route of Administration

• Acne Vulgaris By Stage and Route of Administration

• Acne Vulgaris Assessment by Molecule Type

• Acne Vulgaris by Stage and Molecule Type

DelveInsight’s Acne Vulgaris Report covers around 16+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Acne Vulgaris product details are provided in the report. Download the Acne Vulgaris pipeline report to learn more about the emerging Acne Vulgaris therapies

Some of the key companies in the Acne Vulgaris Therapeutics Market include:

Key companies developing therapies for Acne Vulgaris are – Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation, Galderma SA, Bausch Health Companies Inc, Taro Pharmaceutical Industries Ltd, Tehran University of Medical Sciences, Hamedan University of Medical Sciences, and others.

Acne Vulgaris Pipeline Analysis:

The Acne Vulgaris pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acne Vulgaris with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acne Vulgaris Treatment.

• Acne Vulgaris key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Acne Vulgaris Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acne Vulgaris market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acne Vulgaris drugs and therapies

Acne Vulgaris Pipeline Market Drivers

• High Prevalence, Growing Awareness, Advances in Research, Technological Innovations, Demand for Safer and Effective Treatments, Regulatory Support, are some of the important factors that are fueling the Acne Vulgaris Market.

Acne Vulgaris Pipeline Market Barriers

• However, Complex Disease Mechanisms, Efficacy Challenges, Safety Concerns, High Development Costs, Competitive Landscape, Patient Compliance and other factors are creating obstacles in the Acne Vulgaris Market growth.

Scope of Acne Vulgaris Pipeline Drug Insight

• Coverage: Global

• Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others

• Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others

• Acne Vulgaris Therapeutic Assessment: Acne Vulgaris current marketed and Acne Vulgaris emerging therapies

• Acne Vulgaris Market Dynamics: Acne Vulgaris market drivers and Acne Vulgaris market barriers

Request for Sample PDF Report for Acne Vulgaris Pipeline Assessment and clinical trials

Table of Contents

1. Acne Vulgaris Report Introduction

2. Acne Vulgaris Executive Summary

3. Acne Vulgaris Overview

4. Acne Vulgaris- Analytical Perspective In-depth Commercial Assessment

5. Acne Vulgaris Pipeline Therapeutics

6. Acne Vulgaris Late Stage Products (Phase II/III)

7. Acne Vulgaris Mid Stage Products (Phase II)

8. Acne Vulgaris Early Stage Products (Phase I)

9. Acne Vulgaris Preclinical Stage Products

10. Acne Vulgaris Therapeutics Assessment

11. Acne Vulgaris Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acne Vulgaris Key Companies

14. Acne Vulgaris Key Products

15. Acne Vulgaris Unmet Needs

16 . Acne Vulgaris Market Drivers and Barriers

17. Acne Vulgaris Future Perspectives and Conclusion

18. Acne Vulgaris Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/